What is Epitalon and what is its molecular structure?

Epitalon (also spelled epithalon) is a synthetic tetrapeptide with the amino acid sequence Ala-Glu-Asp-Gly (AEDG). Its molecular formula is C₁₄H₂₂N₄O₉ and its molecular weight is 390.34 g/mol (CAS 307297-39-8). It is the synthetic analogue of epithalamin, a naturally occurring pineal peptide preparation first characterized by Vladimir Khavinson's laboratory in Saint Petersburg.

What does research show about Epitalon's effect on telomere length?

Preclinical and in-vitro studies, including a 2025 study (PMID 41240216) in normal epithelial and fibroblast cell lines, reported dose-dependent telomere length extension associated with upregulation of hTERT mRNA expression and telomerase enzyme activity. In cancer cell lines (21NT, BT474), telomere extension was also observed, primarily via ALT (Alternative Lengthening of Telomeres) pathway activation. Independent replication of these findings has occurred but remains limited relative to the volume of published claims.

How does Epitalon interact with the pineal gland and melatonin?

Animal model studies from Khavinson's laboratory and collaborators reported that epitalon and its parent preparation epithalamin are associated with partial restoration of nocturnal melatonin amplitude in aged rodents with declining pineal function. Proposed mechanisms involve modulation of the hypothalamic-pituitary-pineal axis. Human data on epitalon-induced melatonin changes are absent from the indexed literature.

Is Epitalon FDA-approved or available as a prescription drug?

No. Epitalon is not approved by the FDA, EMA, or any major regulatory body for human therapeutic use. It is classified as an investigational research compound. It is one of the compounds under review at the FDA PCAC July 2026 hearing for 503A bulk compounding list status determination.

What is the difference between Epitalon and Epithalamin?

Epithalamin is a natural polypeptide preparation extracted from bovine pineal glands, containing multiple bioregulator peptides. Epitalon (AEDG) is the synthetic tetrapeptide analogue identified as the primary bioactive sequence within epithalamin. Most published longevity and lifespan research used epithalamin; more recent telomere and molecular mechanism studies use synthetic epitalon. The two are often cited interchangeably in reviews but are chemically distinct.

Epitalon Research Overview: Telomere Biology, Aging & Preclinical Data

Epitalon (Ala-Glu-Asp-Gly; also spelled "epithalon") is a synthetic tetrapeptide derived from the pineal peptide preparation epithalamin, first characterized by Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology. The compound has been studied across four decades of Russian and post-Soviet gerontology research, primarily for its reported effects on telomerase activation, circadian regulation, and longevity-associated biomarkers in animal models.

All content on this page is drawn from peer-reviewed literature and publicly registered research records. It is prepared for laboratory research reference only. Nothing here constitutes medical advice, therapeutic recommendation, or guidance for human use.

Molecular Identity

Sequence: Ala-Glu-Asp-Gly (one-letter: AEDG)
Molecular formula: C₁₄H₂₂N₄O₉
Molecular weight: 390.34 g/mol
CAS number: 307297-39-8
Classification: Tetrapeptide; bioregulator peptide; pineal-derived

Epitalon is the synthetic analogue of the natural pineal tetrapeptide epithalamin. It is water-soluble and stable under standard laboratory storage conditions. Its small molecular size (4 amino acids) distinguishes it from larger peptide hormones and allows high tissue penetration in preclinical models.

Research Background: The Khavinson Laboratory

The majority of published epitalon research originates from or cites the work of Vladimir Khavinson, who holds patents on epithalamin and its synthetic analogues in Russia. Khavinson's group published extensively in journals including Bulletin of Experimental Biology and Medicine, Neuroendocrinology Letters, and Annals of the New York Academy of Sciences from the 1980s through the 2020s.

This concentrated authorship profile is a legitimate methodological consideration when evaluating the literature. Independent replication of Khavinson's findings has occurred in some domains (notably the telomere work; see 2025 Correction noting ALT pathway data) but remains limited relative to the volume of claims made. Researchers are advised to weight independently replicated findings more heavily.

Mechanism 1: Telomerase Activation and Telomere Extension

The most-cited proposed mechanism is epitalon's ability to upregulate telomerase (hTERT) activity, leading to measurable telomere length extension in treated cell cultures.

Key findings from the literature

A 2025 study (PMID 41240216; Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity) examined three cell lines — two breast cancer lines (21NT, BT474) and normal epithelial and fibroblast cells — treated with epitalon. Findings:

Normal cells: qPCR and immunofluorescence demonstrated dose-dependent telomere length extension, attributed to upregulation of hTERT mRNA expression and telomerase enzyme activity.
Cancer cell lines: Significant telomere extension also occurred, primarily through ALT (Alternative Lengthening of Telomeres) pathway activation. Importantly, ALT activity was largely specific to cancer cells, with only minor elevation in normal cells.
The authors conclude that epitalon extends telomere length via distinct mechanisms depending on cell type: hTERT/telomerase in normal cells, ALT in malignant cells.

Earlier work by Khavinson et al. (DOI 10.1023/A:1016027606368) in Bulletin of Experimental Biology and Medicine reported telomere elongation in cultured human fetal fibroblasts following epitalon exposure, with measured increases in telomere length by Q-FISH. This was among the first published reports linking a peptide compound to direct telomere biology.

Mechanistic framing

Telomere shortening is a well-established hallmark of cellular aging; telomerase activation is one mechanism by which stem cells and germline cells maintain telomere length. The proposed model for epitalon is:

Epitalon enters the nucleus or acts on surface receptors → signal transduction cascade
Transcriptional upregulation of TERT (the catalytic subunit of telomerase)
Increased telomerase activity → addition of TTAGGG repeats to chromosome ends
Net effect: reduced rate of replicative senescence in treated cells

Critical gap: The upstream receptor or binding target through which epitalon produces this transcriptional effect has not been definitively characterized. The mechanistic link between AEDG sequence and hTERT promoter activity remains incompletely described in peer-reviewed literature.

Mechanism 2: Pineal Gland and Melatonin Regulation

A second major research thread examines epitalon's reported effects on the hypothalamic-pituitary-pineal axis. Khavinson's group and collaborators reported:

Melatonin restoration: In aged rats with declining nocturnal melatonin secretion, epithalamin and epitalon administration was associated with partial restoration of melatonin amplitude in several studies.
Circadian rhythm parameters: Age-related disruption of the light/dark melatonin cycle was attenuated in treated animal models.
Pinealocyte morphology: Electron microscopy studies reported improved pinealocyte structure (organelle density, secretory granule population) in aged animals treated with pineal bioregulators.

The proposed clinical relevance is that melatonin decline in aging contributes to circadian disruption, immune senescence, and antioxidant capacity loss — all hallmarks of the aging phenotype. Epitalon's reported melatonin-modulating effects position it within the broader neuroendocrine theory of aging framework, which holds that hypothalamic-pituitary signaling deterioration drives systemic aging.

Independent replication status: The melatonin restoration findings have been partially corroborated in independent rodent studies. Human data on epitalon-induced melatonin changes remain absent from the indexed literature.

Longevity and Lifespan Data in Animal Models

Several rodent studies from the Khavinson laboratory reported extended median and maximal lifespan in animals receiving chronic epitalon or epithalamin treatment:

Female Wistar rats given subcutaneous epithalamin (0.1 mg/kg, 5 days per month) reportedly showed 13–25% increases in median lifespan and reduced incidence of spontaneous tumors versus controls.
A similar protocol with CBA mice reported a 3.8–8.2% increase in mean lifespan.
Separate work in Drosophila melanogaster reported lifespan extension of approximately 16% with topical epitalon exposure.

Methodological caveats: These studies were conducted in single-laboratory settings without independent replication at the full-protocol level. Housing conditions, diet controls, and statistical methods in older Russian-language publications may not meet current ARRIVE reporting standards. The tumor-incidence reductions, while frequently cited, have not been replicated in multisite studies.

Antioxidant Research

A subset of the epitalon literature examines reactive oxygen species (ROS) modulation. Reported findings include:

Reduced lipid peroxidation markers (MDA, TBARS) in epitalon-treated aged-rat tissues
Increased superoxide dismutase (SOD) and catalase activity in some tissue compartments
Attenuation of age-associated decline in mitochondrial membrane potential in hepatocyte cultures

The antioxidant data are mechanistically plausible given the well-described relationship between telomere dysfunction, mitochondrial ROS, and p53-mediated senescence signaling. Whether epitalon's antioxidant effects are secondary to telomerase activation or represent an independent mechanism is unresolved.

Regulatory and Safety Context

Epitalon is not approved by the FDA, EMA, or any major regulatory body for therapeutic use in humans or animals. It is classified as an investigational research compound.

In the context of the FDA PCAC (Pharmacy Compounding Advisory Committee) July 2026 review, epitalon is one of the compounds under consideration for 503A category status determination. The key factors the committee evaluates include:

Presence of a clinically demonstrated use in peer-reviewed literature
Whether the compound presents demonstrable safety concerns
Whether it is essentially a copy of an FDA-approved drug

Epitalon does not have an FDA-approved equivalent, which is relevant to Factor 3 of the PCAC analysis. The committee's July 2026 deliberations will address its compounding status; this article will be updated following the hearings.

See: FDA PCAC July 2026 Full Docket Guide and MOTS-C, DSIP, Epitalon & Semax: PCAC Docket Research Summary.

Summary of Research Landscape

Research area	Evidence strength	Independent replication
Telomere elongation (in vitro)	Moderate	Partial (2025 correction study)
Telomerase (hTERT) upregulation	Moderate	Partial
Melatonin/circadian effects (rodent)	Low–Moderate	Limited
Lifespan extension (rodent)	Low–Moderate	Not replicated independently
Antioxidant activity	Low	Limited
Human clinical data	Absent	N/A

Key References

Khavinson VKh et al. "Peptide regulation of aging." Bulletin of Experimental Biology and Medicine. 2004. DOI: 10.1023/A:1016027606368
Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. PMID 41240216. 2025.
Anisimov VN, Khavinson VKh. "Peptide bioregulation of aging: results and prospects." Ageing Research Reviews. 2010. PMID 19932197.

Related compound pages: Epitalon Library Entry · MOTS-C · GHK-Cu · Thymosin Alpha-1
Related articles: Epitalon FDA PCAC Status · Best Peptides for Longevity Research